The short-term effects of stavudine (d4T) plus lamivudine (3TC) were evaluated among 48 human immunodeficiency virus -infected patients for whom zidovudine therapy had failed or who could not tolerate zidovudine. Patients were followed for 8 weeks after initiation of open-label d4T plus 3TC. Four patients discontinued therapy, because of neutropenia (1), hepatitis (1), or neuropathy (2). Reduction in virus load was 00.86 (/0.3 to 03.4) log 10 copies/mL and CD4 cell increase was 30 (0100 to /290) cells/mm 3 . Virologic response was associated with a higher CD4 cell count, no prior exposure to d4T and 3TC, and no previous AIDS-defining illness. Virus load reduction for patients naive to 3TC and d4T was 01.47 (00.14 to 03.37) log 10 copies/mL. Short-term use of d4T plus 3TC is safe, well-tolerated, and associated with virologic and substantial immunologic benefits. Further evaluation of d4T and 3TC in combination is warranted.
A number of controlled trials have now demonstrated that untested combinations. Despite the lack of controlled clinical data, stavudine (d4T) and lamivudine (3TC) have often been combination antiretroviral therapy is generally more effective that monotherapy for the treatment of human immunodeficombined under these circumstances on the basis of their wellcharacterized antiviral effect, nonoverlapping toxicities, and ciency virus (HIV) infection [1 -6] . Survival benefit and improvement of clinical outcomes have been correlated with favorable safety and pharmacokinetic profiles [14 -24] . We report here the results of a pilot open-label study of the short-term changes in surrogate markers of HIV disease progression [7 -9] . In particular, recent evidence suggests that short-term tolerability and antiviral effect of d4T and 3TC combination therapy in the setting of advanced HIV infection changes in plasma virus load within the first 2 months of therapy are predictive of long-term clinical outcome [10 -12] .
among patients who were zidovudine-intolerant or no longer benefiting from zidovudine therapy. These developments have led to a substantial revision of our therapeutic approach based on the use of combination antiretroviral therapy regimens and ongoing monitoring of plasma Methods virus load and CD4 cell counts [13] .
The effect of specific therapeutic regimens on clinical out- from zidovudine therapy have often received treatment with years old and had the following: CD4 cell count õ400 cells/mm 3 , hemoglobin concentration §80 g/L, absolute neutrophil count ú0.6 1 10 9 /L, platelet count ú25 1 10 9 /L, liver function tests õ5 times the upper limit of normal, and serum creatinine level it was specifically contraindicated for use with d4T and 3TC. Direct assay (20 copies/mL) in 2 (4%) of 45 patients. Median log 10 HIV RNA change at week 8 was 01.47, 00.88, and 00.42 copies/mL for patients naive to both study drugs, 3TC, Results and d4T, respectively. The median increase in CD4 cell count at week 8 was 30 Patients' characteristics. A total of 71 consecutive patients were screened, and 58 were enrolled between October 1995 (range, 0100 to /290) cells/mm 3 . Thirty-nine patients (81%) demonstrated an improvement in CD4 cell count during the and April 1996. Five patients discontinued the study before week 4: 1 died (cryptococcal meningitis), 1 was found to have a study. Predictors of virologic response. A full 34 patients (71%) testicular carcinoma and chemotherapy was begun, 1 developed Pneumocystis carinii pneumonia, and 2 stopped both study demonstrated a virologic response ( §0.5 log 10 decrease in plasma HIV RNA at week 4). Baseline characteristics of redrugs because of a newly developed rash. A further 5 subjects failed to comply with the protocol: 2 did not start medications sponders and nonresponders are compared in table 1. As shown in table 2, higher CD4 cell counts at baseline, no prior exposure for personal reasons and 3 failed to return to their appointments. These 10 patients are not included in the analyses. The reto d4T and 3TC, or no previous AIDS-defining illness were associated with a greater likelihood of virologic response with maining 48 patients are henceforth referred to as the study group.
d4T plus 3TC. Other variables, such as baseline plasma HIV RNA and the nature or length of prior exposure to other nucleo-A full 94% of patients were homosexual men; median age was 39 years, and one-third of patients had a prior AIDSsides, were not significantly associated with the likelihood of / 9d39$$no35 09-23-97 11:28:14 jinfa UC: J Infect such a response. Of note, similar results were obtained when substantial antiviral effect, even among heavily pretreated patients with advanced disease. Despite the fact that our study a virologic response was defined as having a §0.5 or 1 log 10 reduction in plasma HIV RNA at 4 or 8 weeks.
group was at increased risk for the development of bone marrow suppression and peripheral neuropathy, the number of patients with grade 3 or 4 toxicities was within rates reported in Discussion previous studies with d4T or 3TC monotherapy [16 -19, 29] . The magnitude of the virologic and immunologic response seen In this pilot study, we have shown that d4T plus 3TC in combination are generally safe and well-tolerated and have in our study group is also noteworthy. We observed a median decrease in plasma HIV RNA of 0.86 log 10 and a median increase in CD4 cell count of 30 cells/mm 3 despite the fact that two-thirds of our study group had been previously exposed We limited our evaluation of d4T plus 3TC to an 8-week period, in the setting of a preliminary pilot study. We cannot advanced disease who were zidovudine-intolerant or clinically 
